Drug
Pasireotide
Pasireotide: highest development phase Post-Market, developed by Recordati. 1 trial record tracked on RxWires.
- Highest phase
- Post-Market
- Developer
- Recordati
Trials
| Drug | Phase | Indication |
|---|---|---|
| Pasireotide NCT01794793 | Post-Market | Cushing's Disease |
Latest
No recent events.
Follow Pasireotide on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.